Bronchiolitis Obliterans Syndrome Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Renovion, Inc., Zambon SpA, Incyte Corp., Chia Tai Tianqing

Posted on
by

Bronchiolitis Obliterans Syndrome Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Renovion, Inc., Zambon SpA, Incyte Corp., Chia Tai Tianqing
The Bronchiolitis Obliterans Syndrome Market size was valued approximately USD 58 Million in 2022 and the report offers an in-depth understanding of the Bronchiolitis Obliterans Syndrome, historical and forecasted epidemiology as well as the Bronchiolitis Obliterans Syndrome market trends in the 7MM.

DelveInsight’s “Bronchiolitis Obliterans Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Bronchiolitis Obliterans Syndrome, historical and forecasted epidemiology as well as the Bronchiolitis Obliterans Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Bronchiolitis Obliterans Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bronchiolitis Obliterans Syndrome Market Forecast

 

Some of the key facts of the Bronchiolitis Obliterans Syndrome Market Report: 

  • The Bronchiolitis Obliterans Syndrome market size was valued approximately USD 58 Million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In January 2024, Renovion has reported the conclusion of enrolling adult patients for its Phase II CLIMB study. This study aims to investigate the therapeutic potential of ARINA-1 in individuals diagnosed with non-cystic fibrosis bronchiectasis. Conducted in the United States, the study is a randomized, double-blind, and placebo-controlled trial, focusing on assessing the safety, tolerability, and efficacy of the therapy.
  • In May 2023, Zambon has finished enrolling patients in its two pivotal Phase III trials evaluating Liposomal Cyclosporine A for Inhalation (L-CsA-i) as a treatment for bronchiolitis obliterans syndrome (BOS). These trials, known as BOSTON-1 and BOSTON-2, are designed to evaluate the safety and effectiveness of L-CsA-i in adults who have developed BOS following single lung or double lung transplantation.
  • In 2023, the number of diagnosed prevalent cases of bronchiolitis obliterans syndrome (BOS) was approximately 34,000 in the 7MM. It is anticipated that this number may rise by 2034.
  • In 2023, approximately 34,000 cases of bronchiolitis obliterans syndrome (BOS) were treated in the 7MM. DelveInsight’s analysts project that the total treated cases of BOS in the 7MM are likely to increase by 2034.
  • In 2023, approximately 14,000 diagnosed prevalent cases of bronchiolitis obliterans syndrome (BOS) were reported in the EU4 and the UK, with expectations for an increase by 2034. Within the EU4 and the UK, Germany had the highest number of diagnosed prevalent cases of BOS in 2023.
  • In 2023, the United States had the highest number of diagnosed prevalent cases of bronchiolitis obliterans syndrome (BOS) among the 7MM, totaling around 18,000 cases. This number is projected to increase by the year 2034.
  • Key Bronchiolitis Obliterans Syndrome Companies: Renovion, Inc., Zambon SpA, Incyte Corp., Chia Tai Tianqing Pharma, Incyte Biosciences, OrphAI Therapeutics, Sanofi, Mallinckrodt, GlaxoSmithKline, Genentech, and others
  • Key Bronchiolitis Obliterans Syndrome Therapies: ARINA-1, Liposomal Cyclosporine A, itacitinib, TQ05105 tablets, INCA034176, LAM-001, Belumosudil, Extracorporeal Photopheresis (ECP), SERETIDE, ESBRIET (pirfenidone), and others
  • The Bronchiolitis Obliterans Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bronchiolitis Obliterans Syndrome pipeline products will significantly revolutionize the Bronchiolitis Obliterans Syndrome market dynamics.

 

Bronchiolitis Obliterans Syndrome Overview

Bronchiolitis obliterans syndrome (BOS) is a serious lung condition that affects the small airways (bronchioles) in the lungs. It is characterized by inflammation and scarring (fibrosis) of the bronchioles, which leads to the narrowing or blockage of these air passages. BOS is most commonly associated with lung transplant recipients as a form of chronic lung allograft dysfunction (CLAD), but it can also occur in individuals who have undergone hematopoietic stem cell transplantation (HSCT) or as a complication of certain respiratory infections.

 

Get a Free sample for the Bronchiolitis Obliterans Syndrome Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/bronchiolitis-obliterans-syndrome-market

 

Bronchiolitis Obliterans Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Bronchiolitis Obliterans Syndrome Epidemiology Segmentation:

The Bronchiolitis Obliterans Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Bronchiolitis Obliterans Syndrome
  • Prevalent Cases of Bronchiolitis Obliterans Syndrome by severity
  • Gender-specific Prevalence of Bronchiolitis Obliterans Syndrome
  • Diagnosed Cases of Episodic and Chronic Bronchiolitis Obliterans Syndrome

 

Download the report to understand which factors are driving Bronchiolitis Obliterans Syndrome epidemiology trends @ Bronchiolitis Obliterans Syndrome Epidemiology Forecast

 

Bronchiolitis Obliterans Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bronchiolitis Obliterans Syndrome market or expected to get launched during the study period. The analysis covers Bronchiolitis Obliterans Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Bronchiolitis Obliterans Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Bronchiolitis Obliterans Syndrome Therapies and Key Companies

  • ARINA-1: Renovion, Inc.
  • Liposomal Cyclosporine A: Zambon SpA
  • itacitinib: Incyte Corp.
  • TQ05105 tablets: Chia Tai Tianqing Pharma
  • INCA034176: Incyte Biosciences
  • LAM-001: OrphAI Therapeutics
  • Belumosudil: Sanofi
  • Extracorporeal Photopheresis (ECP): Mallinckrodt
  • SERETIDE: GlaxoSmithKline
  • ESBRIET (pirfenidone): Genentech

 

Discover more about therapies set to grab major Bronchiolitis Obliterans Syndrome market share @ Bronchiolitis Obliterans Syndrome Treatment Landscape 

 

Bronchiolitis Obliterans Syndrome Market Strengths

  • Improved understanding of the pathogenesis of BOS in different patient populations has led to studies in identifying potential noninvasive biomarkers for the early diagnosis of BOS
  • Different possible disease pathways responsible for BOS progression and loss of lung dysfunction have been studied, helps in identifying new targets for the cure and management of BOS.

 

Bronchiolitis Obliterans Syndrome Market Opportunities

  • Currently, there is only symptomatic treatment available for BOS patients. Both prophylactic treatment therapies and therapies for the cure and management of BOS are yet to be approved.
  • A small but increasing patient pool and governmental support to treat BOS allow companies to market new therapies with higher margins.

 

Scope of the Bronchiolitis Obliterans Syndrome Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Bronchiolitis Obliterans Syndrome Companies: Renovion, Inc., Zambon SpA, Incyte Corp., Chia Tai Tianqing Pharma, Incyte Biosciences, OrphAI Therapeutics, Sanofi, Mallinckrodt, GlaxoSmithKline, Genentech, and others
  • Key Bronchiolitis Obliterans Syndrome Therapies: ARINA-1, Liposomal Cyclosporine A, itacitinib, TQ05105 tablets, INCA034176, LAM-001, Belumosudil, Extracorporeal Photopheresis (ECP), SERETIDE, ESBRIET (pirfenidone), and others
  • Bronchiolitis Obliterans Syndrome Therapeutic Assessment: Bronchiolitis Obliterans Syndrome current marketed and Bronchiolitis Obliterans Syndrome emerging therapies
  • Bronchiolitis Obliterans Syndrome Market Dynamics: Bronchiolitis Obliterans Syndrome market drivers and Bronchiolitis Obliterans Syndrome market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Bronchiolitis Obliterans Syndrome Unmet Needs, KOL’s views, Analyst’s views, Bronchiolitis Obliterans Syndrome Market Access and Reimbursement 

 

To know more about Bronchiolitis Obliterans Syndrome companies working in the treatment market, visit @ Bronchiolitis Obliterans Syndrome Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Bronchiolitis Obliterans Syndrome Market Report Introduction

2. Executive Summary for Bronchiolitis Obliterans Syndrome

3. SWOT analysis of Bronchiolitis Obliterans Syndrome

4. Bronchiolitis Obliterans Syndrome Patient Share (%) Overview at a Glance

5. Bronchiolitis Obliterans Syndrome Market Overview at a Glance

6. Bronchiolitis Obliterans Syndrome Disease Background and Overview

7. Bronchiolitis Obliterans Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Bronchiolitis Obliterans Syndrome 

9. Bronchiolitis Obliterans Syndrome Current Treatment and Medical Practices

10. Bronchiolitis Obliterans Syndrome Unmet Needs

11. Bronchiolitis Obliterans Syndrome Emerging Therapies

12. Bronchiolitis Obliterans Syndrome Market Outlook

13. Country-Wise Bronchiolitis Obliterans Syndrome Market Analysis (2019–2032)

14. Bronchiolitis Obliterans Syndrome Market Access and Reimbursement of Therapies

15. Bronchiolitis Obliterans Syndrome Market Drivers

16. Bronchiolitis Obliterans Syndrome Market Barriers

17.  Bronchiolitis Obliterans Syndrome Appendix

18. Bronchiolitis Obliterans Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/